Wire · opportunities
BEXLUTRY Becomes First FDA-Approved Radioligand Equivalent for Adults With SSTR ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 September 2026 · Fusion42 review
The FDA approved BEXLUTRY (lutetium Lu 177 dotatate; Curium) as the first radioligand equivalent for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) via the 505(b)(2) pathway, providing an additional targeted therapy option that expands treatment availability.
This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it.
◆ ◆ The Wire takeaway
You now face a broader treatment market for somatostatin receptor-positive neuroendocrine tumors as Curium's FDA-approved radioligand equivalent creates a new option beyond LUTATHERA. This opens doors for you to partner with more treatment centres expanding patient access.
◆ Coverage
3 sources · 15 Sep 2026
◆ Related on Wire
◆ Topics